Correlation between treatment outcomes, baseline characteristics and molecular responses in the Majic study which compared Ruxolitinib to best available therapy in essential thrombocythemia

Correlation between treatment outcomes, baseline characteristics and molecular responses in the Majic study which compared Ruxolitinib to best available therapy in essential thrombocythemia

Bibliographic Details
Main Authors:	Harrison, C, Mead, A, Fox, S, Panchal, A, Yap, C, Houlton, A, Aliman, S, Ewing, J, Wood, M, Chen, F, Coppell, J, Panoskaltsis, N, Knapper, S, Ali, S, Hamblin, A, Scherber, R, Geyer, H, Scotch, A, Dueck, A, Cross, N, Mesa, R, McMullin, M
Format:	Conference item
Published:	American Society of Hematology 2016

Similar Items

Ruxolitinib compared with best available therapy for essential thrombocythaemia patients resistant or intolerant to hydroxycarbamide in majic: an investigator lead randomized trial
by: Harrison, C, et al.
Published: (2016)

Ruxolitinib versus best available therapy for ET intolerant or resistant to hydroxycarbamide in a randomized trial
by: Harrison, C, et al.
Published: (2017)

Longitudinal mutational analysis in hydroxycarbamide-resistant/intolerant essential thrombocythemia treated on the majic-ET study
by: O'Sullivan, J, et al.
Published: (2018)

Ruxolitinib induces changes in histone modification status in patients entered into the MAJIC clinical trial
by: McPherson, S, et al.
Published: (2018)

Ruxolitinib for the Treatment of Essential Thrombocythemia
by: Arief Gunawan, et al.
Published: (2018-08-01)

The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib
by: O'Sullivan, JM, et al.
Published: (2019)

Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial
by: Harrison, CN, et al.
Published: (2023)

Numbers do the Majic – Fast Tracking the Game
by: V., Sasirekha
Published: (2013)

Numbers do the majic-fast tracking the game
by: Sasirekha, ,
Published: (2013)

Ruxolitinib as an emerging treatment in myelofibrosis
by: Emanuel RM, et al.
Published: (2013-03-01)

Feasibility of recruitment of patients withMyeloproliferative Neoplasms into the TAPfunded TAMARIN study
by: Harrison, C, et al.
Published: (2018)

Practical management of patients with myelofibrosis receiving ruxolitinib.
by: Harrison, C, et al.
Published: (2013)

P1046: TREATMENT COMPARISON OF HYDROXYUREA VS RUXOLITINIB IN ESSENTIAL THROMBOCYTHEMIA (ET): A MATCHED COHORT ANALYSIS
by: Michael Grunwald, et al.
Published: (2023-08-01)

P989: DYNAMIC CHANGES IN THE HISTONE H3 LYSINE 27 TRIMETHYLATION EPIGENETIC LANDSCAPE FOLLOWING RUXOLITINIB ADMINISTRATION
by: G. Greenfield, et al.
Published: (2022-06-01)

The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms
by: Graeme Greenfield, et al.
Published: (2018-12-01)

Ruxolitinib therapy followed by reduced-intensity conditioning for hematopoietic cell transplantation for myelofibrosis: Myeloproliferative Disorders Research Consortium 114 study
by: Gupta, V, et al.
Published: (2018)

Ankica Čilaš Šimpraga, Dubravka Ivšić Majić, Domagoj Vidović Rječnik suvremenih hrvatskih osobnih imena
by: Ivana Matas Ivanković
Published: (2019-01-01)

RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort
by: O'Sullivan, JM, et al.
Published: (2023)

Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence
by: Harrison, C, et al.
Published: (2016)

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
by: Srdan Verstovsek, et al.
Published: (2023-07-01)

Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis
by: Stephen T. Oh, et al.
Published: (2024-02-01)

Essential thrombocythemia
by: Brière Jean B
Published: (2007-01-01)

Neuromyotonia in association with essential thrombocythemia.
by: Benito-León, J, et al.
Published: (2000)

P1047: REAL-WORLD SAFETY OF RUXOLITINIB IN PATIENTS WITH INTERMEDIATE OR HIGH RISK OF PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS IN CHINA
by: Z. Xu, et al.
Published: (2022-06-01)

Equivalence of BCSH and WHO diagnostic criteria for ET
by: Harrison, C, et al.
Published: (2016)

Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012.
by: Reilly, J, et al.
Published: (2014)

Efficiency of interferon therapy in patients with essential thrombocythemia or polycythemia vera
by: M A Sokolova, et al.
Published: (2016-12-01)

THROMBOTIC AND BLEEDING RISK FACTORS IN ESSENTIAL THROMBOCYTHEMIA
by: A. A. Zhernyakova, et al.
Published: (2017-06-01)

A guideline for the diagnosis and management of polycythaemia vera. A British Society for haematology guideline
by: McMullin, M, et al.
Published: (2018)

A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis
by: McMullin, M, et al.
Published: (2018)

Concomitant essential thrombocythemia and mature B-lymphoproliferative disorder in a patient
by: A. Butt, et al.
Published: (2020-10-01)

S197: NAVITOCLAX PLUS RUXOLITINIB IN JAK INHIBITOR-NAÏVE PATIENTS WITH MYELOFIBROSIS: PRELIMINARY SAFETY AND EFFICACY IN A MULTICENTER, OPEN-LABEL PHASE 2 STUDY
by: F. Passamonti, et al.
Published: (2022-06-01)

Ruxolitinib for the treatment of myelofibrosis: its clinical potential
by: Ostojic A, et al.
Published: (2012-03-01)

Clinical features of essential thrombocythemia and primary myelofibrosis, depending on the molecular characteristics of disease
by: A L Melikyan, et al.
Published: (2017-07-01)

Guideline for the diagnosis and management of myelofibrosis.
by: Reilly, J, et al.
Published: (2012)

Essential Thrombocythemia in Children and Adolescents
by: Maria Caterina Putti, et al.
Published: (2021-12-01)

MODALITY OF TREATMENT IN ESSENTIAL THROMBOCYTHEMIA
by: Lana Macukanovic-Golubovic, et al.
Published: (2008-10-01)

Emerging treatments for essential thrombocythemia
by: Okoli S, et al.
Published: (2011-12-01)

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
by: Harrison, C, et al.
Published: (2005)

Platelet function and blood coagulation system status in childhood essential thrombocythemia
by: Dmitrii M. Polokhov, et al.
Published: (2020-11-01)